Arcadia Biosciences reported a net loss attributable to common stockholders of $6.3 million ($2.09 per share) for the second quarter ended June 30, 2026, compared to a $4.5 million loss in the prior year period. Second-quarter revenues were flat at $1.44 million, while operating expenses decreased by $17,000 due to lower SG&A costs offsetting the absence of prior-year contingent liability gains. The company closed a $4 million private placement in June 2026, ending the quarter with $4.2 million in cash and using only $319,000 in operating cash flow. Zola sales exceeded $740,000 in July, signaling recovery from previous inventory constraints. Arcadia Biosciences is a producer and marketer of innovative wellness products and agricultural ingredients.
